EVFM - Evofem announces peer-reviewed publication on birth control method

• The shares of Evofem Biosciences (WVFM), a biopharma focused on women’s sexual and reproductive health gained in the pre-market Tuesday on above average volume after the company announced a peer reviewed publication of an article on its Phexxi birth control method.
• More than 31.4M Evofem ( NASDAQ: EVFM ) shares have changed hands so far, compared to the 65-day average of 26.9M.
• The article published on the Journal of Therapeutic Advances in Reproductive Health defines and reconfirms the mechanism of action of Phexxi, an FDA-approved, contraceptive vaginal gel available on prescription.
• The article highlights how Phexxi prevents pregnancy given its ability to maintain vaginal pH up to an hour before and during vaginal intercourse.
• Since the recent Supreme Court ruling on abortion rights, Evofem ( EVFM ) has nearly tripled in value, as shown in this graph.

For further details see: